Product category:
Chemicals and biochemicals
News Release from: Molecular Devices | Subject: Imap
Edited by the Laboratorytalk Editorial
Team on 04 December 2003
Binding system makes further progress
Progressive binding system promises enhanced performance for virtually all kinases, phosphatases and phosphodiesterases by addressing key parameters such as substrate limitation
Molecular Devices has announced the launch of the most recent additions to its Imap platform, the Imap progressive binding system and nine new peptide substrates With the Imap progressive binding system, researchers can achieve enhanced performance for virtually all kinases, phosphatases and phosphodiesterases by addressing key parameters such as substrate limitations, ATP concentrations and background levels
This article was originally published on Laboratorytalk on 9 Oct 2006 at 8.00am (UK)
Related stories
Detection for fluorescence polarisation and Fret
Molecular Devices announced in February 2006 the launch of its Imap time resolved fluorescence resonance energy transfer (TR-Fret) homogeneous detection system for its proprietary Imap platform
Removing the assay development roadblock
Assay development is the major roadblock to HTS, and one of the largest barriers to developing an assay for a novel kinase target is finding a suitable substrate
The nine new peptides added to Molecular Devices's growing line of validated peptides further support Imap as a complete systems approach for assaying enzyme activity.
Molecular Devices's Imap technology is rapidly becoming the established assay format to screen for kinase and phosphatase activity because it does not rely on radioactivity or antibodies.
The new binding system and growing list of validated substrates further enable the end user to develop assays for uncommon or proprietary enzymes with the same ease of miniaturisation and low cost-per-well that Imap users have come to expect.
"Kinases and phosphatases are screened at all major pharmaceutical companies, and we believe that Imap is becoming the preferred screening platform.
"Molecular Devices will continue to add key components that provide our customers with the flexibility required to address this important yet diverse class of drug targets," stated Stephen Oldfield, vice president of worldwide marketing at Molecular Devices. Request a free brochure from Molecular Devices ...
"By exploiting the ratiometric format inherent in fluorescence polarisation, Imap leverages Molecular Devices's line of Analyst instruments which are known for setting industry standards in FP detection.".
• Molecular Devices: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
